<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg"/></p>
<p>英国通过 VPAG 计划将 2026 年的创新药物回扣率降低至 14.5%。图片来源：Vitalii Stock via Shutterstock.com。</p>
<p>英国政府将其创新药物回扣率削减超过三分之一，此举可能会受到制药行业的欢迎。</p>
<p>这意味着在 2026 年向英国国家健康服务体系（NHS）提供新一代疗法的制药公司将通过品牌药物定价自愿计划（VPAG）支付 14.5% 的回扣。这一比例较 2025 年的回扣率 22.9% 大幅下降。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>生物制药行业现状 2023</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>法国 - 医疗、监管和报销环境</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>与此同时，2026 年老牌药物的回扣率将保持不变，维持在 10%-35% 之间，具体取决于疗法。</p>
<p>除了对老药和新药的提议回扣率外，NHS 还将通过预种子投资资金组件获得 1% 的资金，这意味着新药的回扣率将达到 15.5%。</p>
<p>根据英国卫生与社会护理部的说法，该计划将提升英国作为临床试验和制造中心的吸引力，同时将该国定位为新药早期上市的有利地点。</p>
<p>这一回扣变化紧随英国政府与特朗普政府达成的 里程碑协议。根据该协议，英国在向美国进口药品时将不再支付关税，使其成为第一个达成此类协议的国家。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预测？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>作为关税豁免的交换，英国将通过 NHS 增加对创新药物的支出，正如该国的药物支出监管机构国家健康与护理卓越研究所（NICE）所允许的。这是 NICE 在过去二十多年中首次提高成本效益阈值。</p>
<p>根据英美协议，英国在 2027 年和 2028 年设定了 15% 的回扣上限，英国制药工业协会（ABPI）首席执行官 Richard Torbett 指出，这将 “为公司提供更大的确定性”，直到截止期。</p>
<p>尽管这是向前迈出的积极一步，Torbett 指出，仍需更多努力使英国重新回到全球竞争的地位：“支付率仍远高于类似国家，NHS 在采用和使用成本效益药物方面还有待加快。”</p>
<p>与此同时，慈善药物获取联盟主席 Scott Purdon 博士赞扬了政府的举措，指出如果回扣减少能带来更大的投资和更广泛的治疗获取，将会带来 “显著的好处”。</p>
<p>GlobalData 健康经济学和市场准入的管理分析师 Janet Beal 指出：“最近达成的 VPAG 回扣上限为 15% 不需要在 2026 年适用，而通过标准机制计算出的较低数字 14.5% 可能会让英国制药行业感到相当惊喜和欢迎。”</p>
<p>展望未来，Beal 预测大多数成员公司 “极有可能” 选择在接下来的一年内继续留在该计划中，因为 “目前设定的 2026 年强制性备份法定计划的回扣率为 24.3% 是一个明显劣势的选择”。</p>
<h2>英国寻求修复制药关系</h2>
<p>通过回扣的变化和与美国的协议，英国正在 努力改善 与制药行业的关系，最近由于对该行业投资不足而变得紧张。</p>
<p>这促使一系列大型制药公司停止在英国的研发扩展努力，包括 MSD、阿斯利康 和赛诺菲。</p>
<p>根据《金融时报》的采访，艾利 Lilly 首席执行官大卫·里克斯称英国 “可能是欧洲药品价格最糟糕的国家”，这在美英协议签署之前。尽管里克斯对协议持乐观态度，但该公司最近告诉该出版物，它尚未准备好解冻在英国的投资。</p>
<p>对英国的生命科学外商直接投资也受到影响，在 2021 年至 2023 年间下降了 58%，这突显了投资者信心可能下降。</p>
<p>英国现在希望通过恢复与行业的关系来扭转其命运。</p>
<p>在一份研究报告中，全球法律公司 Sidley Austin 表示，如果英国有任何机会实现这一目标，该国需要 “保持对生命科学的新承诺和投资”。</p>
<p>Sidley 团队总结道：“英国必须继续利用 MHRA 作为主权监管机构的地位，并消除过于复杂的障碍，以便在英国建立和扩大制药公司。”</p>
<h2>制药技术卓越奖 - 提名已关闭</h2>
<p>制药技术卓越奖 的提名现已关闭。非常感谢所有参与的组织——你们的反馈非常出色，展示了卓越的创新、领导力和影响力。</p>
<p><strong>行动中的卓越</strong></p>
<p>Imagene 的 肿瘤智能 (OI) 套件 荣获精准肿瘤学创新奖，因其改变了制药公司设计和进行肿瘤试验的方式。从 AI 驱动的生物标志物发现到更智能的患者分层，看看 Imagene 如何在癌症药物开发中缩短时间、降低成本和风险。</p>
<p>发现影响</p>

<p>英国在 2026 年将其创新药物回扣率在 VPAG 计划下降低至 14.5%，较 2025 年的 22.9% 有所下降。这一举措旨在改善与制药行业的关系，并提升英国在临床试验和新药上市方面的吸引力。此变化是在一项英美协议之后，该协议免除了英国药品进口的美国关税，同时英国还增加了对创新药物的 NHS 支出。尽管这是一个积极的步骤，但仍需进一步努力以增强英国在制药行业的全球竞争力</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg"/></p>
<p>The UK has reduced the innovative medicines rebate rate for 2026 through the VPAG scheme down to 14.5%. Image credit: Vitalii Stock via Shutterstock.com.</p>
<div class="lb-trans"><p>英国通过 VPAG 计划将 2026 年的创新药物回扣率降低至 14.5%。图片来源：Vitalii Stock via Shutterstock.com。</p>
</div><p>The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to be welcomed by the pharma industry.</p>
<div class="lb-trans"><p>英国政府将其创新药物回扣率削减超过三分之一，此举可能会受到制药行业的欢迎。</p>
</div><p>This means pharma companies providing new, next-generation therapies to the UK’s National Health Service (NHS) in 2026 will now pay 14.5% back through the Voluntary Scheme for Branded Medicines Pricing (VPAG). This is down significantly from the 2025 clawback rate, which sat at 22.9%.</p>
<div class="lb-trans"><p>这意味着在 2026 年向英国国家健康服务体系（NHS）提供新一代疗法的制药公司将通过品牌药物定价自愿计划（VPAG）支付 14.5% 的回扣。这一比例较 2025 年的回扣率 22.9% 大幅下降。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>State of the Biopharmaceutical Industry 2023</h4>
<div class="lb-trans"><h4>生物制药行业现状 2023</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>France - Healthcare, Regulatory and Reimbursement Landscape</h4>
<div class="lb-trans"><h4>法国 - 医疗、监管和报销环境</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Meanwhile, payback rates for older, branded medicines will remain unchanged in 2026, standing at a rate of 10%-35%, depending on the therapy.</p>
<div class="lb-trans"><p>与此同时，2026 年老牌药物的回扣率将保持不变，维持在 10%-35% 之间，具体取决于疗法。</p>
</div><p>In addition to the proposed rates for both older and newer drugs, the NHS will receive 1% through a pre-seed investment funding component, meaning the newer medicines will see a clawback rate of 15.5%,</p>
<div class="lb-trans"><p>除了对老药和新药的提议回扣率外，NHS 还将通过预种子投资资金组件获得 1% 的资金，这意味着新药的回扣率将达到 15.5%。</p>
</div><p>According to the UK’s Department of Health &amp; Social Care, this scheme will boost the UK’s attractiveness as a hub for clinical trials and manufacturing, while positioning the nation as a favourable location for the early launch of new medicines.</p>
<div class="lb-trans"><p>根据英国卫生与社会护理部的说法，该计划将提升英国作为临床试验和制造中心的吸引力，同时将该国定位为新药早期上市的有利地点。</p>
</div><p>This rebate change closely follows the UK Government’s landmark deal with the Trump administration. The agreement will see the UK pay no tariffs on pharmaceutical imports into the US, making it the first country to arrange such a deal.</p>
<div class="lb-trans"><p>这一回扣变化紧随英国政府与特朗普政府达成的 里程碑协议。根据该协议，英国在向美国进口药品时将不再支付关税，使其成为第一个达成此类协议的国家。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预测？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>In exchange for this tariff exemption, the UK will increase its spending on innovative medicines through the NHS, as permitted by the nation’s drug spending watchdog, the National Institute for Health and Care Excellence (NICE). This marks the first increase in the NICE’s cost-effectiveness threshold in more than two decades.</p>
<div class="lb-trans"><p>作为关税豁免的交换，英国将通过 NHS 增加对创新药物的支出，正如该国的药物支出监管机构国家健康与护理卓越研究所（NICE）所允许的。这是 NICE 在过去二十多年中首次提高成本效益阈值。</p>
</div><p>As agreed in the UK-US deal, the UK has placed a 15% clawback cap throughout 2027 and 2028, which Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), noted would “provide companies with greater certainty” until the cut-off period.</p>
<div class="lb-trans"><p>根据英美协议，英国在 2027 年和 2028 年设定了 15% 的回扣上限，英国制药工业协会（ABPI）首席执行官 Richard Torbett 指出，这将 “为公司提供更大的确定性”，直到截止期。</p>
</div><p>Despite this positive step forward, Torbett noted that more work would be necessary to get the UK back into a competitive global position: “Payment rates remain much higher than in similar countries, and there is work to do to accelerate the NHS’s adoption and use of cost-effective medicines.”</p>
<div class="lb-trans"><p>尽管这是向前迈出的积极一步，Torbett 指出，仍需更多努力使英国重新回到全球竞争的地位：“支付率仍远高于类似国家，NHS 在采用和使用成本效益药物方面还有待加快。”</p>
</div><p>Meanwhile, Dr Scott Purdon, chair of the Charity Medicines Access Coalition, praised the government’s move, noting that the announcement will bring “significant benefit” if the clawback reduction results in greater investment and broader therapeutic access.</p>
<div class="lb-trans"><p>与此同时，慈善药物获取联盟主席 Scott Purdon 博士赞扬了政府的举措，指出如果回扣减少能带来更大的投资和更广泛的治疗获取，将会带来 “显著的好处”。</p>
</div><p>Janet Beal, managing analyst of health economics and market access, Europe/CIS at GlobalData noted: “The fact that the recently agreed VPAG headline payback cap of 15% did not need to be applied for 2026, and a lower figure of 14.5% has been calculated by the standard mechanism is likely to come as a considerable and welcome surprise to the UK’s pharma sector.”</p>
<div class="lb-trans"><p>GlobalData 健康经济学和市场准入的管理分析师 Janet Beal 指出：“最近达成的 VPAG 回扣上限为 15% 不需要在 2026 年适用，而通过标准机制计算出的较低数字 14.5% 可能会让英国制药行业感到相当惊喜和欢迎。”</p>
</div><p>Moving forward, Beal predicts that it is “highly likely” that a majority of member companies will opt to remain in the scheme for at least the next year, as the “currently set 24.3% payback rate for 2026 on the mandatory backup Statutory Scheme represents a considerably inferior option”.</p>
<div class="lb-trans"><p>展望未来，Beal 预测大多数成员公司 “极有可能” 选择在接下来的一年内继续留在该计划中，因为 “目前设定的 2026 年强制性备份法定计划的回扣率为 24.3% 是一个明显劣势的选择”。</p>
</div><h2>UK looks to repair pharma relations</h2>
<div class="lb-trans"><h2>英国寻求修复制药关系</h2>
</div><p>Through the change to rebates and its deal with the US, the UK is making strides to improve relations with the pharmaceutical industry, which have recently been souring due to a lack of investment in the sector.</p>
<div class="lb-trans"><p>通过回扣的变化和与美国的协议，英国正在 努力改善 与制药行业的关系，最近由于对该行业投资不足而变得紧张。</p>
</div><p>This has prompted a range of big pharma companies to pull the plug on their UK R&amp;D expansion efforts, including MSD, AstraZeneca and Sanofi.</p>
<div class="lb-trans"><p>这促使一系列大型制药公司停止在英国的研发扩展努力，包括 MSD、阿斯利康 和赛诺菲。</p>
</div><p>It also led Eli Lilly CEO David Ricks to call the UK “probably the worst country in Europe” for drug prices before the signing of the US-UK deal, according to an interview with <em>The Financial Times</em>. The company recently told the publication that it is not yet ready to unfreeze its UK investments, despite Ricks’ optimism following the deal.</p>
<div class="lb-trans"><p>根据《金融时报》的采访，艾利 Lilly 首席执行官大卫·里克斯称英国 “可能是欧洲药品价格最糟糕的国家”，这在美英协议签署之前。尽管里克斯对协议持乐观态度，但该公司最近告诉该出版物，它尚未准备好解冻在英国的投资。</p>
</div><p>Life science foreign direct investment into the UK has also taken a hit, sinking 58% between 2021 and 2023, highlighting a potential drop in investor confidence.</p>
<div class="lb-trans"><p>对英国的生命科学外商直接投资也受到影响，在 2021 年至 2023 年间下降了 58%，这突显了投资者信心可能下降。</p>
</div><p>The UK is now looking to turn its fate around by reviving its relationships with the industry.</p>
<div class="lb-trans"><p>英国现在希望通过恢复与行业的关系来扭转其命运。</p>
</div><p>In a research note, global law company Sidley Austin stated that if the UK was to have any chance of achieving this goal, the nation will need to “maintain its new commitment and investment in life sciences”.</p>
<div class="lb-trans"><p>在一份研究报告中，全球法律公司 Sidley Austin 表示，如果英国有任何机会实现这一目标，该国需要 “保持对生命科学的新承诺和投资”。</p>
</div><p>“It will be necessary for the UK to … continue to take advantage of MHRA’s status as a sovereign regulator, and remove roadblocks that overcomplicate the establishment and scale up of pharma companies in the UK,” the Sidley team concluded.</p>
<div class="lb-trans"><p>Sidley 团队总结道：“英国必须继续利用 MHRA 作为主权监管机构的地位，并消除过于复杂的障碍，以便在英国建立和扩大制药公司。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>制药技术卓越奖 - 提名已关闭</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>制药技术卓越奖 的提名现已关闭。非常感谢所有参与的组织——你们的反馈非常出色，展示了卓越的创新、领导力和影响力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行动中的卓越</strong></p>
</div><p>Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
<div class="lb-trans"><p>Imagene 的 肿瘤智能 (OI) 套件 荣获精准肿瘤学创新奖，因其改变了制药公司设计和进行肿瘤试验的方式。从 AI 驱动的生物标志物发现到更智能的患者分层，看看 Imagene 如何在癌症药物开发中缩短时间、降低成本和风险。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>发现影响</p>
</div>

英国将 2026 年药品回扣率削减三分之一，以重新赢得制药行业的信任